Literature DB >> 16088361

Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: the Rancho Bernardo Study.

Simerjot K Jassal1, Denise von Muhlen, Elizabeth Barrett-Connor, Clifford J Rosen.   

Abstract

Insulin-like growth factor-I (IGF-I) stimulates osteoblast function, inhibits collagen matrix degradation, and is positively associated with bone mineral density in most but not all studies. We previously reported that IGF-I was positively associated with BMD at the spine and hip in women but not men. Insulin-like growth factor binding protein-1 (IGFBP-1), a potent modulator of IGF-I, is expressed in normal osteoblasts and inhibits collagen gene expression in bone, but little is known about the relationship between IGFBP-1 and bone mineral density (BMD). We report a cross-sectional study of serum IGFBP-1 levels and BMD in 1,139 community-dwelling men and postmenopausal women (not using estrogen), aged 44-98. In both sexes, IGFBP-1 levels increased linearly with age (p<0.001) and decreased with body mass index (BMI) quartile (p<0.001). After adjusting for age and BMI, there was no significant association between IGFBP-1 and BMD at the hip or spine. IGF-I and IGFBP-1 were weakly and inversely associated with each other. These findings suggest that if there is an important role for IGFBP-1 in bone metabolism, it is mediated or confounded by weight. Studies are needed to further investigate the relationship between inhibitory components of IGF-1 and bone loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088361     DOI: 10.1007/s00198-005-1973-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  31 in total

1.  Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures.

Authors:  T Sugimoto; K Nishiyama; F Kuribayashi; K Chihara
Journal:  J Bone Miner Res       Date:  1997-08       Impact factor: 6.741

2.  Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.

Authors:  S I Helle; I H Omsjø; S C Hughes; L Botta; G Hüls; J M Holly; P E Lønning
Journal:  Clin Endocrinol (Oxf)       Date:  1996-12       Impact factor: 3.478

Review 3.  Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors.

Authors:  D Le Roith
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

4.  Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men.

Authors:  P Gillberg; H Olofsson; H Mallmin; W F Blum; S Ljunghall; A G Nilsson
Journal:  Calcif Tissue Int       Date:  2001-12-21       Impact factor: 4.333

5.  Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum.

Authors:  Jan Frystyk; Kurt Højlund; Kirsten Nyborg Rasmussen; Søren Peter Jørgensen; Mette Wildner-Christensen; Hans Ørskov
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

6.  Age-related changes in serum insulin-like growth factor-binding proteins in women.

Authors:  L R Donahue; S J Hunter; A P Sherblom; C Rosen
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

7.  Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.

Authors:  Steven Boonen; Clifford Rosen; Roger Bouillon; Andreas Sommer; Malcolm McKay; David Rosen; Steven Adams; Paul Broos; Jan Lenaerts; Jef Raus; Dirk Vanderschueren; Piet Geusens
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

8.  Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity.

Authors:  J U Weaver; J M Holly; P G Kopelman; K Noonan; C G Giadom; N White; S Virdee; J A Wass
Journal:  Clin Endocrinol (Oxf)       Date:  1990-09       Impact factor: 3.478

9.  Evidence for an in vivo role of insulin-like growth factor-binding protein-1 and -2 as inhibitors of collagen gene expression in vitamin C-deficient and fasted guinea pigs.

Authors:  A Gosiewska; S Wilson; D Kwon; B Peterkofsky
Journal:  Endocrinology       Date:  1994-03       Impact factor: 4.736

10.  Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients.

Authors:  Peter M. Jehle; Klaus Schulten; Walter Schulz; Daniela R. Jehle; Sylvia Stracke; Burkhard Manfras; Bernhard O. Boehm; David J. Baylink; Subburaman Mohan
Journal:  Eur J Intern Med       Date:  2003-02       Impact factor: 4.487

View more
  3 in total

1.  The role of IGF-I and IGFBP-1 status and secondary hyperparathyroidism in relation to osteoporosis in elderly Swedish women.

Authors:  H Salminen; M Sääf; H Ringertz; L E Strender
Journal:  Osteoporos Int       Date:  2007-09-14       Impact factor: 4.507

2.  Influence of insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 on bone health: results from the European Male Ageing Study.

Authors:  Stephen R Pye; Bader Almusalam; Steven Boonen; Dirk Vanderschueren; Herman Borghs; Evelien Gielen; Judith E Adams; Kate A Ward; Gyorgy Bartfai; Felipe F Casanueva; Joseph D Finn; Gianni Forti; Aleksander Giwercman; Thang S Han; Ilpo T Huhtaniemi; Krzysztof Kula; Fernand Labrie; Michael E J Lean; Neil Pendleton; Margus Punab; Alan J Silman; Frederick C W Wu; Terence W O'Neill
Journal:  Calcif Tissue Int       Date:  2011-04-19       Impact factor: 4.333

3.  Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study.

Authors:  Inga-Lill Engvall; Björn Svensson; Birgitta Tengstrand; Kerstin Brismar; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2008-11-05       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.